Microphysiological Systems | InSphero

Multiply the predictive power of 3D InSight™ Microtissues

InSphero engineered its microphysiological discovery platform to be compatible with our complete portfolio of 3D InSight™ microtissues, opening the door to a near unlimited variety of pre-clinical efficacy and toxicity testing applications in a multi-tissue, microfluidic assay format. From early prototypes conceived as part of the EU Body-on-a-Chip Project, our purpose has been to provide a pharma-ready microfluidic device for integrating advanced 3D microtissues.

The MPS discovery platform provides experimental continuity between single- and multi-tissue testing applications, enabling the seamless integration and optimal utilization of standardized 3D models from a single provider. Complete systems include pre-qualified 3D InSight™ Microtissues, media, assays, and a tilting-based flow control.

  • Minimize cell, medium and compound use in a miniaturized 10-microtissue configuration that increases cell-to-media volume ratio up to 10-fold
  • Leverage maximum physiological complexity while minimizing operational complexity with an automation-compatible, tubeless, tilting-based medium perfusion system to interconnect assay-ready advanced 3D models
  • Compare numerous conditions in parallel on one plate allowing for the first-time throughput-compatible testing with a truly scalable microphysiological system not limited in the number of statistical replicates it can accommodate
  • Rely on a diverse array of experimental endpoints ranging from cell-based and biochemical assays to on-chip high-content imaging, with flexible liquid sampling and non-disruptive microtissue retrieval

Stay informed on the latest platform developments

for 3D InSight™ Microtissues in our newsletter

References

Peer-reviewed Papers

Global Recognition for the EU Body-on-a-Chip Project